

Yasser Perera Negrin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9203762/publications.pdf>

Version: 2024-02-01

34
papers

792
citations

516215

16
h-index

525886

27
g-index

43
all docs

43
docs citations

43
times ranked

795
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting of Protein Kinase CK2 Elicits Antiviral Activity on Bovine Coronavirus Infection. <i>Viruses</i> , 2022, 14, 552.	1.5	4
2	CIGB-300-Regulated Proteome Reveals Common and Tailored Response Patterns of AML Cells to CK2 Inhibition. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 834814.	1.6	4
3	Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 206-212.	2.5	27
4	Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945. <i>Cells</i> , 2021, 10, 338.	1.8	7
5	Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300. <i>Biomedicines</i> , 2021, 9, 766.	1.4	15
6	Evaluation of Cell-Penetrating Peptides as Mucosal Immune Enhancers for Nasal Vaccination. <i>International Journal of Peptide Research and Therapeutics</i> , 2021, 27, 2873-2882.	0.9	2
7	Preclinical efficacy of CIGB-300, an anti-CK2 peptide, on breast cancer metastatic colonization. <i>Scientific Reports</i> , 2020, 10, 14689.	1.6	12
8	CIGB-300 anticancer peptide regulates the protein kinase CK2-dependent phosphoproteome. <i>Molecular and Cellular Biochemistry</i> , 2020, 470, 63-75.	1.4	28
9	Clinical-Grade Peptide-Based Inhibition of CK2 Blocks Viability and Proliferation of T-ALL Cells and Counteracts IL-7 Stimulation and Stromal Support. <i>Cancers</i> , 2020, 12, 1377.	1.7	12
10	Implication of B23/NPM1 in Viral Infections, Potential Uses of B23/NPM1 Inhibitors as Antiviral Therapy. <i>Infectious Disorders - Drug Targets</i> , 2019, 19, 2-16.	0.4	15
11	The Combination of the CIGB-300 Anticancer Peptide and Cisplatin Modulates Proteins Related to Cell Survival, DNA Repair and Metastasis in a Lung Cancer Cell Line Model. <i>Current Proteomics</i> , 2019, 16, 338-349.	0.1	0
12	Characterization of low-abundance species in the active pharmaceutical ingredient of CIGB-300: A clinical-grade anticancer synthetic peptide. <i>Journal of Peptide Science</i> , 2018, 24, e3081.	0.8	9
13	CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation. <i>Seminars in Oncology</i> , 2018, 45, 58-67.	0.8	40
14	CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models. <i>Lung Cancer</i> , 2017, 107, 14-21.	0.9	30
15	Predicting CK2 beta-dependent substrates using linear patterns. <i>Biochemistry and Biophysics Reports</i> , 2015, 4, 20-27.	0.7	7
16	Pharmacologic inhibition of the CK2-mediated phosphorylation of B23/NPM in cancer cells selectively modulates genes related to protein synthesis, energetic metabolism, and ribosomal biogenesis. <i>Molecular and Cellular Biochemistry</i> , 2015, 404, 103-112.	1.4	7
17	Bio-analytical method based on MALDI-MS analysis for the quantification of CIGB-300 anti-tumor peptide in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 105, 107-114.	1.4	5
18	CIGB-300: A Promising Anti-Casein Kinase 2 (CK2) Peptide for Cancer Targeted Therapy. , 2015, , 281-298.		2

#	ARTICLE	IF	CITATIONS
19	Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specific cell-permeable peptide inhibitor. <i>Oncotarget</i> , 2014, 5, 258-263.	0.8	34
20	Synergistic interactions of the anti-casein kinase 2 CIGB-300 peptide and chemotherapeutic agents in lung and cervical preclinical cancer models. <i>Molecular and Clinical Oncology</i> , 2014, 2, 935-944.	0.4	28
21	Mechanisms of Cellular Uptake, Intracellular Transportation, and Degradation of CIGB-300, a Tat-Conjugated Peptide, in Tumor Cell Lines. <i>Molecular Pharmaceutics</i> , 2014, 11, 1798-1807.	2.3	18
22	Sensitivity of tumor cells towards CIGB-300 anticancer peptide relies on its nucleolar localization. <i>Journal of Peptide Science</i> , 2012, 18, 215-223.	0.8	28
23	CIGB-300, a proapoptotic peptide, inhibits angiogenesis in vitro and in vivo. <i>Experimental Cell Research</i> , 2011, 317, 1677-1688.	1.2	20
24	CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoacceptor domain. Translational and clinical research. <i>Molecular and Cellular Biochemistry</i> , 2011, 356, 45-50.	1.4	41
25	Proteomic Profile Regulated by the Anticancer Peptide CIGB-300 in Non-Small Cell Lung Cancer (NSCLC) Cells. <i>Journal of Proteome Research</i> , 2010, 9, 5473-5483.	1.8	26
26	Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1189-1196.	1.9	62
27	Identification of new meningococcal serogroup B surface antigens through a systematic analysis of neisserial genomes. <i>Vaccine</i> , 2009, 28, 532-541.	1.7	20
28	CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo. <i>Molecular and Cellular Biochemistry</i> , 2008, 316, 163-167.	1.4	86
29	Epitope mapping of anti-human transferrin monoclonal antibodies: potential uses for transferrin-transferrin receptor interaction studies. <i>Journal of Molecular Recognition</i> , 2008, 21, 103-113.	1.1	2
30	Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice. <i>International Journal of Cancer</i> , 2008, 122, 57-62.	2.3	64
31	Bicistronic expression plasmid for the rapid production of recombinant fused proteins in <i>Escherichia coli</i> . <i>Biotechnology and Applied Biochemistry</i> , 2006, 44, 27.	1.4	10
32	Fast and novel purification method to obtain the prostate specific antigen (PSA) from human seminal plasma. <i>Prostate</i> , 2006, 66, 1029-1036.	1.2	15
33	Determination of human transferrin concentrations in mouse models of neisserial infection. <i>Journal of Immunological Methods</i> , 2006, 311, 153-163.	0.6	7
34	Development and validation of a quantitative ELISA for the measurement of PSA concentration. <i>Clinica Chimica Acta</i> , 2002, 317, 55-63.	0.5	89